Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with cisplatin and 5-fluorouracil induction therapy for EBV-positive nasopharyngeal carcinoma
2022-500676-59-00Phase 2Authorised
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Dec 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab, cisplatin and fluorouracil in nasopharyngeal carcinoma (NPC), sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoint: Complete remission rate. Planned start Dec 2022; status: authorised.
02
Drugs
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on 2022-500676-59-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500676-59-00.